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The function of intestinal immunity is to provide protection toward pathogenswhile preserv-
ing the composition of the microﬂora and tolerance to orally fed nutrients. This is achieved
via a number of tightly regulated mechanisms including production of IgA antibodies by
intestinal plasma cells. Celiac disease is a common gut disorder caused by a dysfunctional
immune regulation as signiﬁed, among other features, by a massive intestinal IgA autoan-
tibody response. Here we review the current knowledge of this B-cell response and how
it is induced, and we discuss key questions to be addressed in future research.
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The immune system has evolved multiple strategies to maintain
intestinal homeostasis. A unique feature of intestinal immunity is
the ability to provide protection toward pathogens while preserv-
ing the number and composition of the commensal bacteria in a
state of mutualism (Hooper andMacpherson,2010). Secretory IgA
is considered to be one of the crucial immune effectormechanisms
in maintaining homeostasis at mucosal surfaces (Brandtzaeg et al.,
1999; Strugnell and Wijburg, 2010). Therefore, it is not surprising
that themucosal immune compartment is tightly regulated. In this
review, we aim at summarizing and discussing the basic concepts
of intestinal immunobiology in the context of a prevalent disor-
der, celiac disease. The study of this condition provides unique
understanding of how an intestinal IgA response is induced and
reshaped from the healthy to the affected intestinal state, as well
as it pinpoints areas of scarce knowledge and poses key questions
for future research.
FEATURES OF INTESTINAL IMMUNITY
THE INTESTINAL IMMUNE SYSTEM
The generation of secretory IgA is conﬁned to intestinal lymphoid
microenvironments that are composed of the inductive and the
effector tissue compartments (Brandtzaeg and Pabst, 2004). The
inductive compartment of the intestinal immune system consists
of gut-associated lymphoid tissue (GALT) and the regional lymph
nodes, whereas the effector compartment consists of the lamina
propria (LP) and surface epithelia. Together, these form the largest
effector organ of humoral immunity, containing at least 80% of
the body immunoglobulin (Ig)-producing cells (Brandtzaeg and
Johansen, 2005).
GUT-ASSOCIATED INDUCTIVE LYMPHOID TISSUE
The GALT is the main site for the induction of mucosal IgA B cells.
The GALT is comprised of aggregated lymphoid follicles, termed
Peyer’s patches and isolated lymphoid follicles. Gut-associated
lymphoid follicles are organized structures covered with a spe-
cialized follicle-associated epithelium that contains microfold cells
(M cells; Neutra, 1999). In the canonical pathway, antigens from
the gut lumen are internalized and delivered to subepithelial den-
dritic cells (DCs) via M cells or receptor-mediated endocytosis by
epithelial cells (Neutra et al., 2001). Antigen-loaded DCs migrate
from the subepithelial dome into the perifollicular T cell-rich area,
where they can induce a response of helper T cells (Rimoldi et al.,
2005). B cells become activated by the presentation of antigens
from follicular DCs (Harwood and Batista, 2010) and by CD40-
mediated signals from antigen-primed helper T cells (Elgueta
et al., 2009). Gut-associated lymphoid follicles are, therefore,
characterized by germinal centers (GC) that promote antigen-
speciﬁc interaction between T and B cells, an essential mechanism
for B cell differentiation and diversiﬁcation. The GALT further
drives intestinal IgA production by providing cytokines with
IgA-inducing functions, including transforming growth factor-β
(TGF-β; Gonnella et al., 1998; Stavnezer and Kang, 2009), retinoic
acid (RA; Mora et al., 2006), IL-6 (Sato et al., 2003), and inducible
nitric oxide synthase (iNOS; Tezuka et al., 2007). These events lead
to up-regulation of the gene encoding for the enzyme activation-
induced deaminase (AID), which is central to both class-switch
recombination and somatic hypermutation of Ig genes (Mura-
matsu et al., 2000). This T cell-dependent pathway usually results
in generation of plasma cells (PCs) producing intestinal IgA anti-
bodies with high rates of somatic hypermutation (SHM), as well as
memory B cells (Bemark et al., 2012). CD40-mediated signal from
T cells is crucial to GALT GC initiation (Bergqvist et al., 2006),
although it is possible that human intestinal GC-associated B cell
responses are not exclusively dependent on cognate T cell/B cell
interactions (Spencer et al., 2012). Studies have indicated that
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GCs can appear in Peyer’s patches and mesenteric lymph nodes
without the need for the classic T cell/B cell interaction based
on BCR speciﬁcity (Casola et al., 2004). Accordingly, SHM can
take place as an antigen-independent process without being nec-
essarily linked to afﬁnity maturation (Reynaud et al., 1995; Casola
et al., 2004). B cells that are activated in this way are thought
to depend on “bystander” T cell help in the form of cytokines
such as IL-5, IL-6, and IL-10 in order to induce an IgA response
(Jiang et al., 2004).
T cell-independent intestinal IgA responses have been reported
in both humans (Ferrari et al., 2001; Levesque et al., 2009) and
mice (Guy-Grand et al., 1975; Mombaerts et al., 1994). In mice a
T cell-independent, antigen-driven pathway in response to highly
conserved microbial antigens recognized by Toll-like receptors
(TLRs; Cerutti, 2008) generates a primitive intestinal IgA anti-
body repertoire to commensal bacteria (Macpherson et al., 2000;
Bergqvist et al., 2006, 2010). TLR-triggered class switching to
IgA is mediated by BAFF and APRIL expression in DCs, mono-
cytes, macrophages, granulocytes, and intestinal epithelial cells
(Fayette et al., 1997; Litinskiy et al., 2002; Cerutti et al., 2011).
T cell-independent intestinal IgA responses in mice originate
from peritoneal and intestinal LP B-1 cells as well as conven-
tional follicular B-2 cells (Fagarasan et al., 2010). Thus, it has been
suggested that the intestinal LP may act as a potential site for T
cell-independent IgA induction. A lack of consensus, as well as a
lack of homology between murine and human models (Gibbons
and Spencer, 2011) as the human equivalent of mouse B-1 cells
is still not well described (Descatoire et al., 2011), does however
exist when it comes to the LP being a site for IgA class switch-
ing and diversiﬁcation (Fagarasan and Honjo, 2000; Macpherson
et al., 2000; Fagarasan et al., 2001; Shikina et al., 2004; Boursier
et al., 2005; Crouch et al., 2007; He et al., 2007; Barone et al., 2009).
Although T cell-independent responses are biologically possible
and certainly relevant in mice, in humans their contribution to
the intestinal IgA repertoire remains uncertain.
GUT-ASSOCIATED EFFECTOR LYMPHOID TISSUE
The intestinal LP acts as the effector compartment of the humoral
mucosal immune response, and contains predominantly termi-
nally differentiated PCs (Farstad et al., 2000). These are character-
ized by the expression of the markers CD138 and CD27, whereas
levels of CD19 and CD45 are more heterogeneous; the lack of
expression of the Ki-67 marker indicates that these cells are not
blasting and should therefore be referred to as PCs rather than
as plasmablasts (Di Niro et al., 2010). Human intestinal PCs pref-
erentially produce IgA dimers (80%) and IgM pentamers (20%),
whereas a small fraction produces IgG (Brandtzaeg et al., 1999;
Brandtzaeg and Johansen, 2005). The amount of Ig produced by
intestinal PCs is massive, being estimated at 3 g/day in adults
(Brandtzaeg and Johansen, 2005). Dimeric IgA is formed of two
monomeric IgA units joined by a bridging J chain that is recog-
nized by the polymeric Ig receptor (pIgR), an antibody transporter
expressed on the basolateral surface of epithelial cells (Brandtzaeg
and Prydz, 1984; Johansen et al., 2001). Upon interaction with
pIgR, dimeric IgA is translocated to the surface of epithelial cells
as secretory IgA where it exerts its function of immune exclusion,
intracellular neutralization, and antigen excretion (Cerutti and
Rescigno, 2008; Strugnell and Wijburg, 2010). The intestinal LP
in addition to PCs contains a variety of other cell types, includ-
ing macrophages, DCs, and neutrophils which in association with
epithelial cells may play a crucial role in creating and maintaining
the niche for PC survival (Benson et al., 2008).
Antigen-speciﬁc IgA antibodies generated upon immunization
can be identiﬁed only locally (Ogra and Karzon, 1969) or both
systemically and locally (Crabbe et al., 1969) depending on the
immunization strategy. These observations, together with the fact
that IgA reactive to commensal bacteria is exclusively present in
gut secretions (Macpherson et al., 2000), support the notion of
mucosal immunity as an independent compartment. Rotavirus-
speciﬁc memory B cells were shown to have different antibody
repertoires (Weitkamp et al., 2003) than effector mucosal PCs
(DiNiro et al., 2010),which raises somequestions about the nature
of the interplay between these two compartments.
THE INTESTINAL IgA REPERTOIRE
In principle, both unmutated IgA antibodies with broad reactivity
to self and non-self antigens and somatically mutated antigen-
speciﬁc IgA antibodies could contribute to the intestinal PC
repertoire. There are several observations suggesting that the latter
pathway may be dominating. Barone et al. (2011) reported results
supporting GC origin of human intestinal IgA-producing PCs.
Cloning and sequencing of Ig variable region genes of IgA PCs
from LP of human small intestine revealed uniformly high degrees
of SHM and high ratios of replacement to silent (R/S) mutations
in complementarity determining regions (CDR), which argues in
favor of antigen-mediated selection (Dunn-Walters et al., 1997;
Boursier et al., 1999). Our group isolated human intestinal PCs
speciﬁc to rotavirus and cloned antibody genes, observing high
numbers of mutations (17 mutations per sequence on average,
with an R/S of 2.3, in the VH only; Di Niro et al., 2010). Similarly,
Benckert et al. (2011) cloned hundreds of human monoclonal
antibodies (hmAbs) fromIgAand IgG intestinal plasmablasts from
the ileum of healthy donors. Regardless of their reactivity, the anti-
bodies had many mutations, averaging 23 in theVH. The majority
of the antibodies were speciﬁc for foreign or self antigens whereas
25% were polyreactive. Only 7% of IgA displayed cross-reactivity
with diverse bacterial strains. To note, the polyreactive antibodies
also had high degree of SHM suggesting that antibody polyreac-
tivity of gut plasmablasts may be acquired by somatic mutations.
Selection of somatically mutated variants of polyreactive antibod-
ies may simultaneously act as a parallel mechanism in deﬁning
and contributing to antigen-speciﬁc immune response against for-
eign antigens. Revision of light chains expressed by IgA PCs is
another distinct feature of human intestinal PCs and it is conﬁned
to gene rearrangements at the lambda loci (Su et al., 2008). This
has been suggested as a beneﬁcial mechanism in order to diver-
sify the intestinal IgA repertoire and to remove non-functional or
autoreactive antibodies.
Contrary to initial studies suggesting that the intestinal IgA
repertoire is oligoclonal and of low diversity (Dunn-Walters et al.,
1997; Holtmeier et al., 2000; Yuvaraj et al., 2009), Lindner et al.
(2012) using a high-throughput sequencing method, recently
demonstrated that the intestinal IgA population in mice is highly
polyclonal. The repertoire is comprised of both highly expanded
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and low frequency clones, and with age new clones are introduced.
Notably, expanded clones with previously selected speciﬁcities
repopulated the small intestine after PC depletion and showed
similar SHM frequencies, hence indicating the presence of a func-
tional intestinal IgA memory compartment. A polyclonal and
highly diverse IgA repertoire would parallel the broad range of
intestinal antigens to which the intestinal mucosa is constantly
exposed, although it also appears that the repertoire continuously
adapts to the current composition of the microﬂora (Hapfelmeier
et al., 2010). The high-throughput analysis of the intestinal IgA
repertoire performed by Lindner et al. (2012) also suggested that
clonal expansion is likely to occur predominantly in the periphery
rather than locally in the LP, which has been a subject of debate in
previous studies (Yuvaraj et al., 2009).
Taken together, these studies strongly indicate that the great
majority of gut IgA antibodies develop from antigen-speciﬁc B cell
responses, which evolve by acquisition of somatic mutations to
confer effectiveness and high speciﬁcity.
LONGEVITY OF INTESTINAL IgA PLASMA CELLS
Another matter of debate has been whether human intestinal IgA
PCs can provide long-term humoral immunity. Evidence for a
long-lived, commensal-speciﬁc IgA response was observed when
germ-free mice were reversibly colonized by bacteria (Hapfelmeier
et al., 2010). In absence of competition from newly generated cells,
IgA PCs were shown to have a half-life of at least 16 weeks. The
dynamic of such IgA response, however, reﬂected the contents of
the intestinal lumen, suggesting that the number of long-lived
PC niches is limited. As a consequence, in presence of com-
petition such as that deriving from the continuously evolving
microﬂora, “older” PCs – despite their long-lived potential – are
constantly displaced by new ones, which are generated in response
to the most recent stimuli. In agreement with these observations,
we have demonstrated that the human small intestine harbors a
population of non-proliferating PCs that are maintained by the
local supportive microenvironment for long-term survival (Mesin
et al., 2011). Moreover, an inﬂammatory microenvironment may
enhance the niche capacity, resulting in more robust PC responses
(Radbruch et al., 2006).
MUCOSALLY INDUCED TOLERANCE
The homeostatic role of the intestinal immune system is to provide
suppressed immune responses as to generate mucosally induced
tolerance. Such tolerance can be directed toward orally adminis-
tered antigens or toward gut bacteria. Thus, there are two layers of
intestinal anti-inﬂammatory homeostatic mechanisms: immune
exclusion of commensal bacteria by secretory antigen-speciﬁc IgA
and immune suppression to avoid hypersensitivity to innocuous
food antigens. These two mechanisms of mucosally induced tol-
erance appear to act independently in order to attenuate a broad
range of immune responses (Weiner et al., 2011; Pabst and Mowat,
2012). The lack of such homeostatic tolerance results in intestinal
immune pathology. Active proinﬂammatory immune responses
directed toward the gut microbiota, inducing imbalance in IgA
and IgG repertoires, are associate with the development of inﬂam-
matory bowel disease, such as Crohn’s disease and ulcerative colitis
(Baklien and Brandtzaeg, 1976; Macpherson et al., 1996). In celiac
disease (CD) there is an active proinﬂammatory immune response
to cereal gluten antigens.
CELIAC DISEASE
Celiac disease is a common intestinal disorder affecting 1% of
the population in Europe and the US, although only a fraction
of patients is readily diagnosed due to the highly variable clinical
presentation of the disease (Green, 2005). CD can be considered
a food intolerance to wheat gluten (consisting of the gliadin and
glutenin subcomponents) and related proteins from rye and bar-
ley. In genetically predisposed individuals, gluten ingestion can
cause an inﬂammatory reaction in the upper small intestine which
gives tissue damage leading to villous atrophy (Sollid, 2002). The
lesion and inﬂammatory changes disappear after weeks or months
when patients for treatment purpose commence a gluten-free diet
(GFD). The inﬂammatory reaction appears to be driven by acti-
vation of Th1-like CD4+ T cells (see Box 1) that recognize gluten
peptides post-translationally modiﬁed by the enzyme transglu-
taminase 2 (TG2; Molberg et al., 1998; van de Wal et al., 1998).
What initiates this “aggressive” T cell response and lack of oral
tolerance to gluten is not known. It has been suggested that some
part of gluten may have innate properties or that infections may
play a role (reviewed in Jabri and Sollid, 2009). In steady-state
conditions, the maintenance of intestinal homeostasis is initi-
ated by intestinal DCs that are affected by enterocyte-derived
factors, such as retinoic acid and TGF-β, conferring tolerogenic
properties on the DCs. Tolerogenic DCs educate the intesti-
nal immune system to respond in a non-inﬂammatory manner
to orally administered proteins by the induction of regulatory
T (Treg) cells. An alteration of the intestinal environment, as
observed in CD, characterized by a high level of inﬂammatory
cytokines such as IL-15 and IFNα, may affect the acquisition of
the tolerogenic phenotype of intestinal DCs. This will prevent the
induction of Treg cells, further promoting the differentiation of
proinﬂammatory T cells (Jabri and Sollid, 2009). Interestingly,
beside the strong gluten-speciﬁc T cell response, CD presents
autoimmune features, most notably the production of autoan-
tibodies. These antibodies are primarily directed against TG2
(Dieterich et al., 1997), but antibodies speciﬁc for other autoanti-
gens like actin, collagen and others have also been described
(Alaedini and Green, 2008). Whereas the T cell response to gluten
has been thoroughly characterized and is relatively well under-
stood, signiﬁcantly less is known about the B cell responses
in CD.
TG2 has several biological functions which include transami-
dation (cross-linking) and deamidation, and is involved in many
physiological processes (Lorand and Graham, 2003). TG2 is
present in large amounts in the gut LP, in particular in a sub-
epithelial layer. It is hardly coincidental that TG2 is also the
target of the autoantibodies in CD. Studies based on in situ detec-
tion with immunoﬂuorescence (Korponay-Szabo et al., 2004) and
phage display antibody libraries (Marzari et al., 2001) suggested
that anti-TG2 antibodies are produced locally in the small intes-
tine, and recently we were able to visualize the intestinal PCs
producing such antibodies (Di Niro et al., 2012). In the following,
we will describe the current knowledge and the future directions
in the study of the intestinal B cell response in CD.
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BOX 1 | Immunopathogenesis of CD.
CD is a multifactorial disease with a complex interplay between
genetic and environmental factors eventually leading to chronic
inﬂammation (see Abadie et al., 2011; Meresse et al., 2012 for
review and references therein). Of these factors, the most sig-
niﬁcant genetic component is HLA; 90% of celiac patients carry
a variant of DQ2 termed DQ2.5, whereas most of the remain-
ing patients carry DQ8. The HLA association has been extensively
investigated, and the study of lesion-derived T cell lines and T cell
clones has allowed a detailed description of gluten T cell epitopes.
Several epitopes exist and some epitopes are more frequently rec-
ognized than others (reviewed in Sollid et al., 2012). An important
feature of both the DQ2.5 and DQ8 molecules is their preference
for binding of negatively charged amino acid residues (i.e., gluta-
mate or aspartate) in certain binding pockets (P4, P6, and P7 for
DQ2.5; P1 and P9 for DQ8). Gluten proteins have very few neg-
atively charged residues, however they carry a high amount of
glutamine and proline residues. Interestingly, glutamine can be
deamidated to glutamate by the enzyme TG2, and TG2-modiﬁed
gluten peptides show strong immunogenicity. This suggests that,
under particular circumstances, deamidation happens in vivo, lead-
ing to the formation of post-translationally modiﬁed gluten peptides
that are suitable for presentation by DQ2.5 or DQ8 molecules. The
gluten T cell epitopes are furthermore hallmarked by the presence
of multiple proline residues, and this is particularly so for epitopes
presented by DQ2.5. Proline, in addition to inﬂuencing MHC bind-
ing, exerts a force in the selection ofT cell epitopes at two additional
levels. First, peptides rich in proline are resistant to proteolysis, and
proline-rich gluten peptides survive gastrointestinal digestion allow-
ing them to reach the LP where they can by loaded on HLA-DQ
molecules expressed by antigen-presenting cells. Second, proline
guides the speciﬁcity of TG2 so that glutamine residues in the
motif glutamine-X-proline are targeted. Notably, the peptides har-
boring T cell epitopes in a complex gluten digest are the preferred
TG2 substrates. How these forces work can be visualized by look-
ing at the α2-gliadin, a representative α-gliadin. Upon treatment
with gastric and pancreatic endopeptidases a relatively large frag-
ment, the 33-mer LQLQPFPQPQLPYPQPQLPYPQPQLPYPQPQPF
(residues 57 to 89), survives digestion. Due to its length this
peptide is resistant to digestion by small intestinal brush-border
membrane ectopeptidases aswell.Three glutamine residueswithin
the 33-mer are deamidated byTG2.This deamidated 33-mer harbors
six overlapping T cell epitopes and is an extremely potent anti-
gen. Upon recognition of deamidated gluten peptides, the CD4+
T cells become activated and start producing cytokines including
interferon-γ and interleukin-21. The priming of the gluten-speciﬁc
CD4+ T cells likely takes place in GALT or mesenteric lymph nodes
and the primed cells seed via the blood into the LP as effector
cells. TheseT cells may be important for forming PC survival niches
in the LP.
THE INTESTINAL B CELL RESPONSE IN CD
The celiac lesion is characterized by considerable expansion of the
PC population (Douglas et al., 1970; Soltoft, 1970) and enhanced
local immunoglobulin secretion (Lancaster-Smith et al., 1974;
Wood et al., 1987). In addition, there are IgA deposits at the epithe-
lial basementmembrane of the small intestine (Shiner and Ballard,
1972; Korponay-Szabo et al., 2004) which can be observed without
overt histological changes (Salmi et al., 2006a). The plasmacytosis
(increased median PCs per mucosal tissue unit of 2.1, 3.8, and
2.9-fold for IgA, IgM, and IgG respectively; Baklien et al., 1977;
Scott et al., 1980) may relate to bolstering of a PC survival niche.
Local plasmacytosis in CD appears to be homeostatic with an
unaltered immunoglobulin isotype distribution and marked pre-
ponderance of IgA PCs (Brandtzaeg, 2006). Notably, the duodenal
IgA PC population in active CD maintains mucosal phenotype
by J-chain expression and consists of a higher proportion of the
IgA2 subclass than in the normal duodenal mucosa (Kett et al.,
1990). Upon dietary gluten restriction, intestinal PC numbers are
reduced (Holmes et al., 1973).
ANTI-GLIADIN AND ANTI-TG2 ANTIBODIES
Early experiments performed by ELISA,ELISpot, and immunoﬂu-
orescence indicated local intestinal secretion of anti-gliadin anti-
bodies (Stern and Dietrich, 1982; Ciclitira et al., 1986; Labrooy
et al., 1986; Lycke et al., 1989). These studies suggested that gliadin-
speciﬁc PCs account for 1–2, 10 and 5–10% of total IgA, IgM, and
IgG PCs, respectively, in the small intestine of CD patients. Anti-
gliadin IgA and IgG antibodies are detected in sera of untreated
CD patients and can be harnessed as a diagnostic tool. These anti-
bodies disappear after commencement of a GFD (Savilahti et al.,
1983; Kilander et al., 1987), and they rise again when gluten is
reintroduced into the diet (Koninckx et al., 1984). Thus, their level
seems to mirror the immune reaction triggered by gluten in the
intestine and, further, their decrease is related to a clinical improve-
ment of the intestinal mucosa (Mayer et al., 1989; Valletta et al.,
1990). IgA gliadin-speciﬁc B cells have been detected in periph-
eral blood of CD patients (Hansson et al., 1997; Sblattero et al.,
2000); these possibly are circulating IgA plasmablasts homing
to the LP.
Celiac disease patients also develop autoreactive antibodies
originally identiﬁed as targeting connective tissue constituents, in
particular the endomysium (Chorzelski et al., 1983). The enzyme
TG2was identiﬁed as themajor endomysial autoantigen (Dieterich
et al., 1997). In the diagnostic workup of CD, assessment of serum
of anti-TG2 autoantibodies has become an important tool for the
diagnosis particularly in children where new recommendations
allow the diagnosis to be made without histological examina-
tion of small intestinal biopsies (Husby et al., 2012). Similarly
to anti-gliadin antibodies, the production of anti-TG2 antibod-
ies is dependent on dietary gluten exposure (Dieterich et al., 1998;
Sulkanen et al., 1998). Anti-TG2 antibody titers have been shown
to correlate with abnormal small intestine histopathology (Tursi
et al., 2003).While serum anti-gliadin antibodies have a signiﬁcant
IgA2 component, only a minor portion of serum IgA antibodies
reactive to the endomysium were found to belong to this subclass
(Osman et al., 1996).
Recently, we demonstrated that TG2-speciﬁc PCs can be visu-
alized by immunoﬂuorescence of tissue sections (Figure 1) and by
ﬂow cytometry of single-cell suspensions from duodenal biopsy
specimens (Di Niro et al., 2012). To note, TG2-speciﬁc PCs com-
prise 4–24% of the total IgA PC population in the celiac lesion.
This massive accumulation of TG2-speciﬁc PCs is further sup-
ported by the notion that IgA intestinal antibody deposits target
the same antigen in the extracellular matrix and the endothe-
lium of the small blood vessels (Korponay-Szabo et al., 2004),
thus reﬂecting an abundant local antibody production. Notably,
TG2-targeted IgA intestinal deposits are present at all stages of
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FIGURE 1 | A patch with high frequency ofTG2-specific PCs as revealed by immunofluorescence analysis on a cryosection of the duodenal mucosa of
a patient with active CD. Staining performed with biotinylatedTG2 (biot-TG2, followed by ﬂuorescent streptavidin, green), a plasma cell marker (anti-CD138,
red ), and a nuclei stain (DAPI, blue).
CD, including early developing CD (prior to villous atrophy;
Kaukinen et al., 2005; Paparo et al., 2005; Tosco et al., 2008) as
well as the advanced lesion stage in rare seronegative patients
(Salmi et al., 2006b).
CHARACTERISTICS OF THE ANTI-TG2 ANTIBODY REPERTOIRE
In our recent, thorough dissection of the antibody (Ab) repertoire
of the intestinal autoimmune response to TG2, we found that
despite extensive class switch to IgA, antibody genes had a very
limited amount of somatic mutations (Di Niro et al., 2012). From
the analysis of 60 sequences of heavy chain variable region genes
cloned from single intestinal PCs of CD patients, we observed on
average less than half the number of mutations found in the rest of
the intestinal PC compartment. Interestingly, anti-TG2 antibodies
with heavy chain encoded by the VH5 gene, which accounted for
44% of the response, were signiﬁcantly less mutated than those
encoded by other genes, including several that were entirely germ-
line encoded. A trend of low mutation in VH5 genes in the gut
was observed before (Boursier et al., 1999), but the reason for this
and for the preferential recruitment of cells expressing antibodies
encoded by VH5 in the autoimmune repertoire is not known. It
may be related to structural properties of theVH5 region and/or to
the fewermutational hotspots in theVH5–51 gene.Worthnoting is
that a number of VH5 antibodies with different speciﬁcity did not
bind TG2 to any extent, thus showing that the anti-TG2 reactivity
is CDR-encoded and not depending on unspeciﬁc binding of the
VH5 framework regions (Di Niro et al., 2012).
This signiﬁcantly differs from all other intestinal human anti-
body repertoires described to date, as presented and discussed
above, in which antibody genes with such a limited number of
mutations were seldom observed. This represents a unique feature
of the anti-TG2 response and may therefore provide clues into its
generation.
GENERATION OF TG2-SPECIFIC B CELLS
A schematization of the current knowledge and hypotheses for
the generation of the intestinal TG2-speciﬁc B cell response is
shown in Figure 2. The scheme assumes a T cell-dependent mech-
anism for generation of the response. Does instead the observed
phenotype, with scarce SHM, indicate a T cell-independent one?
Indeed, despite numerous efforts, to date there is no convinc-
ing evidence for the existence of TG2-speciﬁc T cells. However,
the clinical observation of the strict HLA-dependent appearance
of TG2-speciﬁc antibodies speaks against this model. In a pop-
ulation based cohort study, Bjorck et al. (2010) compared the
presence of TG2-speciﬁc antibodies in children with or without
the DQ2 or DQ8 HLA-risk alleles, and found that 73 of 1620
(4.5%) individuals with HLA-risk alleles were positive for anti-
TG2 antibodies, versus none of 1815 subjects without HLA-risk
alleles. This strongly suggests T cell involvement. How to recon-
cile these data with the inability to identify TG2-speciﬁc T cells?
Once again, clinical observations provide clues: anti-TG2 anti-
bodies rapidly disappear when gluten is removed from the diet
(Dieterich et al., 1998; Sulkanen et al., 1998). The regulation of the
B cell response by gluten intake is the foundation of the “hapten-
carrier-like model” proposed several years ago (Sollid et al., 1997).
In this model, intestinal gluten-speciﬁc T cells provide help to
TG2-speciﬁc B cells. This is possible because of the enzymatic
activity of TG2. The enzyme can form covalently linked complexes
between itself and glutenpeptides (Fleckenstein et al., 2004),which
then can act as “hapten-carrier-like” complexes. Upon withdrawal
of gluten from the diet, the T cell helpwill cease and anti-TG2 anti-
bodies will disappear. Although this model has not been formally
demonstrated in vivo, we recently provided in vitro evidence that
TG2-speciﬁc B cells indeed can present gluten peptides to gluten-
reactive T cells when offered TG2–gluten peptide complexes
(Di Niro et al., 2012).
Based on strong clinical evidence, T cells thus appear to be
involved in the generation of the anti-TG2 B cell response. In what
is regarded as the “canonical” response, T and B cells cooperate in
the GC, where B cells not only class-switch, but also accumulate
mutations so that clones with increased afﬁnity are selected (afﬁn-
ity maturation) in a process that ultimately generates memory B
cells and long-lived PCs. In particular, B cell memory is “designed”
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FIGURE 2 | Schematic representation of the inductive and effector sites
for the mucosal B-cell response in CD.Through yet unknown mechanisms,
gluten peptides (GP) cross the epithelium and become deamidated gluten
peptides (DGP) by the action of transglutaminase 2 (TG2). These peptides are
then transported, possibly by dendritic cells, to local lymphoid tissue
structures where a strong, proinﬂammatory T cell response takes place.
Some native peptides may reach the lymphoid tissue and may become
targeted byTG2 there. In lymphoid tissuesTG2-speciﬁc B cells likely interact
with gluten-speciﬁc T cells, according to the hapten-carrier-like model
described in the text which builds on the ability of TG2 to formTG2-GP/DGP
complexes. The B cell response generated follows either a canonical germinal
center (GC) pathway or an extrafollicular pathway, resulting in massive
plasmablast generation. The plasmablasts migrate via the blood to the lamina
propria, where they mature as plasma cells (PC), secrete antibodies (Abs) and
survive for extended time in what is called a PC survival niche. In active CD,
this results in plasmacytosis and sustained secretion of IgA dimers (dIgA) –
as well as IgM pentamers – which are transported across the epithelium to
the lumen as secretory IgA (sIgA). TG2-speciﬁc antibodies produced at this
site are also deposited on the subepithelial layer of TG2. BCR, B cell receptor;
FDC, follicular dendritic cell; TCR, T cell receptor.
to respond more rapidly to a secondary antigen challenge, and
repeated stimulation leads to the generation of a switched response
composed of high afﬁnity clones which have acquired many muta-
tions. In humans, this is clear in the cases of HIV, inﬂuenza, and
rotavirus infections (Wrammert et al., 2008; Scheid et al., 2009;
Di Niro et al., 2010).
A possible scenario to explain the phenotype of the anti-
TG2 response is that it is generated at extrafollicular sites, thus
bypassing GC formation (MacLennan et al., 2003) but nonethe-
less maintaining the requirement for T cell involvement. In
mice, this has been observed in more than one context, such as
Salmonella infection (Cunningham et al., 2007) and, interestingly,
the autoimmune RF response (William et al., 2002). Contrary to
what commonly thought, AID can be expressed at EF sites (Mar-
shall et al., 2011), and in the autoimmune context SHM has clearly
been shown to vigorously take place at this site (William et al.,
2002). The intestinal environment may play a role in this process.
AID-dependent class switching to IgA at the LP level has been
shown in mice (Fagarasan et al., 2001) and studies in humans sug-
gested that proliferation, class-switching, and SHM could take
place in the intestinal LP (He et al., 2007; Yuvaraj et al., 2009). As
discussed above, a study of mice based on analysis of IgA sequences
obtained by high-throughput sequencing suggested instead that
extra-mucosal expansion is followed by massive seeding in the
LP, of which clonal relatedness is a consequence (Lindner et al.,
2012). Although still being a matter of major debate, it cannot
be excluded that the TG2-speciﬁc response expands and evolves
in the LP, and that B cells do not enter GCs at all. If they do, the
scarce number of mutations suggests that they undergo limited
rounds of selection, possibly a single one, in the GC. The scope
of the GC is to ultimately produce memory cells and long-lived
PCs. Does this happen in the case of the anti-TG2 response? For
both cell populations evidence is limited and further studies are
required. Upon gluten removal the TG2-speciﬁc IgA serum titer
decreases within months (Maki et al., 1998), suggesting that the
long-lived PC compartment is limited. Although ﬁnally differ-
entiated to a PC phenotype, IgA PCs in the small intestine are
only relatively long-lived, with a lifespan of some months (Mesin
et al., 2011); the microenvironment is likely to play a major role.
Similarly, we have only partial evidence for the existence of a TG2-
speciﬁc, IgA memory compartment in CD, which appears to be
more substantial in GFD-treated rather than active CD patients.
It has to be noted that small amounts of memory B cells seem
to be produced also in the absence of GCs (Toyama et al., 2002;
Foote and Kearney, 2009).
POSSIBLE REGULATION MECHANISMS OF THE ANTI-TG2
IMMUNE RESPONSE
Whether cells are or not generated in GCs, undoubtedly speciﬁc
factors limit GC activity. To note, the diagnosis of CD (and thus
specimen sampling) often occurs many months or years after the
appearance of the symptoms. Moreover, the anti-TG2 response
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precedes symptoms and intestinal damage. All the patients from
whomwe obtained intestinal specimenswere adults (DiNiro et al.,
2012); the anti-TG2 response had likely been present for several
months or years. In this time frame, according to the canonical
model of immune response, GCs should be formed, memory gen-
erated, upon secondary stimulation memory cells preferentially
and rapidly reactivated, resulting in extensive afﬁnity maturation
and accumulation of mutations. What inhibits this? Our cur-
rent knowledge only allows speculation. Several different, and not
mutually exclusive, scenarios can be envisaged.
(i) Feedback mechanisms. These could happen both at the
antibody and the antigen level, as well as at the cellular level.
The extent of the anti-TG2 response (10% of intestinal PCs, on
average) and the consequent massive antibody production may
provide a negative feedback that inhibits GC activity. This could
be seen as a self-regulating mechanism of the immune system.
With regard to antigen availability, chronic stimulation (i.e., con-
tinuous gluten ingestion) may be different than repeated antigen
challenge (i.e., seasonal ﬂu infections). Another feedback mecha-
nism may result from antigen-speciﬁc, isotype-switched PCs that
before homing to the LP act as potent antigen presenting cells.
PC-controlled antigen presentation was shown to suppress the
development and function of antigen-speciﬁc follicular helper
T cells (Pelletier et al., 2010). Such function of PCs would cre-
ate bidirectional regulation of adaptive immunity by providing a
negative cognate regulatorymechanismwhichmay serve as a func-
tional sensor of PC production that can control ongoing GC B cell
responses.
(ii) Afﬁnity. The binding strength of the anti-TG2 antibodies
may be a factor. Even when a panel of mutated anti-TG2 hmAbs
was reverted to their germline counterparts, strong binding to
TG2 was observed (Di Niro et al., 2012). This is atypical as in
the case of anti-ﬂu antibodies removal of mutations gave a dra-
matic loss in afﬁnity (Di Niro et al., 2012). It has been previously
shown in mice that high afﬁnity may favor EF T cell-dependent
PC responses (Chan et al., 2009). Alternatively, it may be that
inside GCs it is afﬁnity that regulates the fate of B cells – i.e.,
whether to become a memory B cell or PC – and that high
afﬁnity favors the latter. In both scenarios, this would result in
generation of a scarce memory compartment and, irrespective
of the speciﬁc mechanism, to continuous activation of naïve B
cells thus explaining scarce SHM. As an alternative explanation,
it has been shown that the initial afﬁnity of the B cell receptor
(BCR) is inversely correlated with accumulation of mutations in
GC T cell-dependent antibody responses in vivo (Shih et al., 2002).
This effect was due to GC selection, as both high and low afﬁn-
ity B cells had the same frequency of mutations in non-coding
sequences.
(iii) T cell control. T cells may represent an important regula-
tor. It has been shown that a robust and efﬁcient T cell response
increases the magnitude of the PC response while preventing
GC recycling and memory cell differentiation (Fujihashi et al.,
1991; Bolduc et al., 2010; Heiser et al., 2011). Furthermore, it has
been suggested that the decision to become a PC upon receiving
T cell help is antigen dose-dependent (Victora and Nussenzweig,
2012). If the help to TG2-speciﬁc B cells indeed is provided
by gliadin-speciﬁc T cells, the amount of antigen and strength
of the T cell response would be compatible with a limited GC
reaction.
(iv) Nature and location of the response. The nature (autoim-
mune) and the location (intestine) differ from any other B cell
responses that have been characterized in humans, and hence
models for comparison are not easily available. In mice, peritoneal
reservoirs of B1 cells signiﬁcantly contribute to intestinal responses
(Kroese et al., 1995) – often via T cell-independent mechanisms,
that do not efﬁciently form GCs (Toellner et al., 2002). Whether
similar mechanisms take place in humans is not fully understood
(Grifﬁn andRothstein, 2012). Could instead the unique features of
the anti-TG2 response relate to the self nature of the antigenic tar-
get? Does the immune system sense the antigen as self and redirects
the response toward an EF one? Germ-line encoded autoreactivity
has been described, for instance in RA (Victor et al., 1991), but
does not seem to be the general rule. In mice, there are notable
examples of autoimmune responses developing at EF sites – the
response to RF being such one situation (William et al., 2002).
Important insights will come from the analysis of the repertoire
of the gluten-speciﬁc B cell response. Would gluten-speciﬁc PCs
show SHM at the same level as TG2-speciﬁc PCs, or would they
have high degrees of SHM as generally seen in intestinal IgA PCs?
Together with the investigation of the CD-speciﬁc B cell memory,
this is one of the most interesting immunological aspects toward
which research should focus.
(v) Structural features. Asmentioned above, anti-TG2 antibod-
ies have high afﬁnity even when germ- line encoded. What confers
such high afﬁnity and, in particular, what favors VH5 selection
over other V regions is not known. On the surface of a B cell, BCR
cross-linking is one potent mechanism for activation. We recently
showed that, in vitro, TG2 can mediate covalent cross-linking of
IgD (and, to a minor extent, IgM, but not of IgA or IgG) antibod-
ies, providing a hypothetical model where continuous activation
of naïve B cells is favored over IgA-switched memory cells, thus
explaining lack of accumulated mutations (Di Niro et al., 2012).
Similarly, it is conceivable that the VH5 dominance is based on a
similar mechanism.
To address these questions, we need to know more about how
antibodies bind to TG2. The hmAbs that we have cloned from
intestinal IgA PCs represent a unique tool to better understand
their interaction with TG2. We are currently investigating the epi-
topes recognized by the autoantibodies, as well as their ability to
bind TG2 in its different forms (i.e., free vs bound to ﬁbronectin,
open vs close conformation,GTP vsCa2+-bound, etc). Ultimately,
fundamental insights will derive from efforts directed toward the
generation of crystal structures of TG2-hmAb complexes.
TG2-SPECIFIC B CELLS AS ANTIGEN PRESENTING CELLS
AMPLIFYING THE ANTI-GLUTEN T CELL RESPONSE
B cells can program CD4+ T cell responses (reviewed in Barr et al.,
2012). This is so, much because B cells and T cells interact in an
antigen-speciﬁc manner. By BCR-mediated uptake and concen-
tration of antigen, B cells serve as potent antigen-presenting cells
for T cells (Lanzavecchia, 1985). This mechanism is essential for
B cells to receive cognate T cell help, but notably it has also direct
consequences for the T cells. B cell-mediated antigen presenta-
tion leads to proliferation and clonal expansion of antigen-speciﬁc
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T cells (Crawford et al., 2006). If TG2-speciﬁc B cells are able
to load deamidated gluten peptides for presentation to gluten-
speciﬁc T cells in vivo (Sollid et al., 1997), this would likely result
in expansion of gluten-speciﬁc T cell clones. These gluten-speciﬁc
T cells would then be able to interact both with TG2-speciﬁc
B cells as well as with B cells speciﬁc for deamidated gluten pep-
tides. Collectively, these eventswill support the antibody responses
to TG2 and deamidated gluten peptides and importantly lead
to an ampliﬁcation of the anti-gluten T cell response. In this
scenario, B cells would be at the center stage of the immunopatho-
genesis of CD, and could therefore be a potential target for
therapy even if CD is considered primarily a T cell-mediated
disease.
PATHOGENIC ROLE AND INTERACTION OF AUTOANTIBODIES
WITH INTESTINAL STRUCTURES
Since the discovery of autoantibodies in CD, and subsequently the
identiﬁcation of TG2 as themain target, there has been speculation
about whether the antibodies themselves are pathogenic. Most
research has focused on the effects of antibodies on enzymatic
activity, with discordant results (Esposito et al., 2002; Dieterich
et al., 2003; Di Niro et al., 2012). A reason for this could be the
variety of assays and experimental conditions used to assess TG2
activity. Although in some casesweak inhibitionhas been reported,
as of now there is no compelling evidence that the effects of autoan-
tibodies on TG2 play a major role, either in the pathogenesis or
in relation to the clinical features of CD. The great majority of
the hmAbs from our newly generated panel neither inhibited nor
enhanced TG2 activity, consistent with a central role for TG2 in
the enzymatic deamidation of gluten peptides.
Among other proposed effects, anti-TG2 antibodies could con-
tribute to the formation of the lesion by inhibiting angiogenesis
(Myrsky et al., 2008) as well as by interfering with the differen-
tiation of epithelial cells (Halttunen and Maki, 1999). Effector
function of antibodies could contribute to the tissue damage seen
in CD. Complement-dependent inﬂammation has been observed
in the CD lesion (Halstensen et al., 1992). Unlike IgA, IgM does
ﬁx the complement, and TG2-speciﬁc IgM are indeed produced
in patients, especially in those with IgA deﬁciency (Borrelli et al.,
2010; Di Niro et al., 2012).
Celiac disease patients with active disease have increased trans-
port of gliadin peptides across the epithelium (Schumann et al.,
2008), and IgA antibodies have also been suggested to have a
role in such transport (Rauhavirta et al., 2011). In the intestinal
mucosa TG2 binds ﬁbronectin, forming a sub-epithelial layer, and
in patients IgA/IgM deposits are observed at this location. More-
over, IgA is found on the brush border. Matysiak-Budnik et al.
(2008) have shown that gliadin peptides can be retro-transcytosed
as IgA–gliadin complexes via the transferrin receptor, which is
abnormally expressed at the apical surface of enterocytes in active
CD. TG2 localized at the apical side of the epithelium may as well
play a role in this mechanism (Lebreton et al., 2012). In the LP,
intact immunostimulatory gliadin peptides might act by trigger-
ing a local immune response and promoting inﬂammation. We
hypothesize that dimeric anti-TG2 IgA play a role in this mech-
anism. Anti-TG2 antibodies could detach TG2 from ﬁbronectin
and the complexes could be transported across the epithelium,
where sampling of gliadin peptides by TG2 itself or by anti-gliadin
antibodies could take place. We have preliminary evidence that
a fraction of anti-TG2 antibodies can in fact compete for the
ﬁbronectin binding site.
In conclusion, as of now the evidence for a role of anti-TG2
antibodies is scarce, and it derives from in vitro or cell culture
systems; when anti-TG2 antibodies were expressed in vivo in mice
(Di Niro et al., 2008), no obvious effect was seen. This highlights
the need for the generation of an animal model of CD.
ANIMAL MODELS OF CD
Several animal models have been developed that try to recapitu-
late CD, however none of them entirely succeeded reproducing the
complex mechanisms causing this disease (reviewed in Marietta
and Murray, 2012). Expression of anti-TG2 autoantibodies in vivo
by means of adeno-associated virus-based gene transfer led to life-
time production of such antibodies, analogous to what observed
in patients, but no clinical features were associated (Di Niro et al.,
2008). Some signs of disease were obtained when pre-sensitized
CD4+ T cells were transferred in Rag-deﬁcient mice, inducing
weight loss and duodenitis (Freitag et al., 2009); however also this
system was not able to recapitulate the majority of the immune
features observed in CD. Interestingly, Jabri’s group has described
a humanized HLA-DQ8-transgenic mouse model (DePaolo et al.,
2011), characterized by over-expression of IL-15 in the LP. When
gliadin-fed, these animals develop IFN-γ-producing anti-gliadin
T cells, anti-gliadin and anti-TG2 antibodies, and intraepithelial
lymphocytosis. Despite lacking the hallmark of villous atrophy,
this model does resemble early stages of CD. Mice are not the
only species where CD models are investigated, as a screening
of macaques also led to identiﬁcation of animals with signs and
symptoms of CD (Bethune et al., 2008); the usefulness of such
model remains to be evaluated. In general, efforts are being made
toward the generationof an animalmodel of CD,whichwill greatly
facilitate research.
THE MICROFLORA AND ITS IMPACT ON INTESTINAL IMMUNITY
Genetic factors may account only for about half of the risk to
develop CD thus leaving an important role for the environment in
the pathogenesis. Gluten exposure obviously is critical, but envi-
ronmental factors outside of gluten may be implicated as well.
Such factors could be pathogenic infectious agents or commensal
bacteria. Recently, it has become clear that the gut microﬂora pro-
foundly inﬂuence intestinal immunity (Kau et al., 2011). There is
a complex interplay between intestinal immunity and the popula-
tions of commensal bacteria, and these two components regulate
each other. Not only does the microﬂora regulate several aspects of
the innate and adaptive immunity, as well as of several metabolic
pathways, but it has also been shown that dysregulated immu-
nity (for instance as a consequence of experimental manipulation
of molecules such as PD-1 and AID; Wei et al., 2011; Kawamoto
et al., 2012) results in skewed gut microbial communities, and this
in turn may have detrimental effects. In future, it will be of major
importance to understand how the microbial communities con-
tribute to the intestinal immune response in a context such as CD
where both the T and the B cell intestinal populations seem altered
as compared to healthy individuals.
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CONCLUSION
In the last two decades we have learnt a lot about CD and its
interplay with intestinal immunity. Among the most remarkable
discoveries, TG2 has been identiﬁed as the main autoantigen of
CD, and its role in creating potent T cell epitopes has been unrav-
eled. We have made huge steps forward in understanding the role
of HLA genes, and many non-HLA susceptibility genes have been
identiﬁed. Some limited progress has also been made in under-
standing the role of innate immunity factors in CD. Recently,
the knowledge of the intestinal B cell response in CD has sig-
niﬁcantly improved. We have learnt that anti-TG2 antibodies
form deposits in the small intestine, a number of highly sensitive
serological tests based on serum antibodies have been developed,
monoclonal antibodies have been isolated by phage display and
single cell cloning, and the cells producing these antibodies have
been visualized, characterized and enumerated. However, many
important features of CD, in particular related to the intesti-
nal environment in which the disease takes place, remain to be
tackled. These include characterization of the anti-gliadin B-cell
response, the IgG anti-TG2 repertoire, identiﬁcation of the mem-
ory compartment, and others. A better understanding of human
intestinal immunobiology is needed to address these questions.
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